Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Smit

Showing results (321-330 of 692) with videos related to

Pageof 70
Sort By:
Basic Research in Cardiology|February 27, 2015
Plasma from human volunteers subjected to remote ischemic preconditioning protects human endothelial cells from hypoxia-induced cell damageNina C Weber, Isabelle Riedemann, Kirsten F Smit, et al.
British Journal of Cancer|August 1, 2018
Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC that express HER2 after progression on EGFR TKI treatmentAdrianus J de Langen, M Jebbink, Sayed M S Hashemi, et al.
Lung Cancer (Amsterdam, Netherlands)|May 19, 2015
Is the current diagnostic algorithm reliable for selecting cases for EGFR- and KRAS-mutation analysis in lung cancer?Julien P L Vincenten, Egbert F Smit, Katrien Grünberg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 26, 2000
A phase I-II study of gemcitabine and paclitaxel in advanced non-small-cell lung cancer patientsG Giaccone, E F Smit, J P van Meerbeeck, et al.
Journal of Natural Products|September 23, 2000
Inhibition of T-lymphocyte proliferation by cucurbitacins from Picrorhiza scrophulariaefloraH F Smit, A J van den Berg, B H Kroes, et al.
Molecular Imaging and Biology|July 2, 2013
Methodological considerations in quantification of 3'-deoxy-3'-[18F]fluorothymidine uptake measured with positron emission tomography in patients with non-small cell lung cancerVirginie Frings, Adrianus J de Langen, Maqsood Yaqub, et al.
Current Pharmaceutical Design|September 15, 2012
Molecular mechanisms and modulation of key pathways underlying the synergistic interaction of sorafenib with erlotinib in non-small-cell-lung cancer (NSCLC) cellsE Giovannetti, M Labots, H Dekker, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|April 13, 2010
Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometryR Honeywell, K Yarzadah, E Giovannetti, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 29, 2010
The finding of premalignant lesions is not associated with smoking cessation in chemoprevention study volunteersRomane M Schook, Berber B M Postmus, Remco M van den Berg, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 10, 2002
Methods to monitor response to chemotherapy in non-small cell lung cancer with 18F-FDG PETCorneline J Hoekstra, Otto S Hoekstra, Sigrid G Stroobants, et al.
Pageof 70

Showing results (321-330 of 692) with videos related to

Sort By:
Pageof 70
Basic Research in Cardiology|February 27, 2015
Plasma from human volunteers subjected to remote ischemic preconditioning protects human endothelial cells from hypoxia-induced cell damageNina C Weber, Isabelle Riedemann, Kirsten F Smit, et al.
British Journal of Cancer|August 1, 2018
Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC that express HER2 after progression on EGFR TKI treatmentAdrianus J de Langen, M Jebbink, Sayed M S Hashemi, et al.
Lung Cancer (Amsterdam, Netherlands)|May 19, 2015
Is the current diagnostic algorithm reliable for selecting cases for EGFR- and KRAS-mutation analysis in lung cancer?Julien P L Vincenten, Egbert F Smit, Katrien Grünberg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 26, 2000
A phase I-II study of gemcitabine and paclitaxel in advanced non-small-cell lung cancer patientsG Giaccone, E F Smit, J P van Meerbeeck, et al.
Journal of Natural Products|September 23, 2000
Inhibition of T-lymphocyte proliferation by cucurbitacins from Picrorhiza scrophulariaefloraH F Smit, A J van den Berg, B H Kroes, et al.
Molecular Imaging and Biology|July 2, 2013
Methodological considerations in quantification of 3'-deoxy-3'-[18F]fluorothymidine uptake measured with positron emission tomography in patients with non-small cell lung cancerVirginie Frings, Adrianus J de Langen, Maqsood Yaqub, et al.
Current Pharmaceutical Design|September 15, 2012
Molecular mechanisms and modulation of key pathways underlying the synergistic interaction of sorafenib with erlotinib in non-small-cell-lung cancer (NSCLC) cellsE Giovannetti, M Labots, H Dekker, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|April 13, 2010
Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometryR Honeywell, K Yarzadah, E Giovannetti, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 29, 2010
The finding of premalignant lesions is not associated with smoking cessation in chemoprevention study volunteersRomane M Schook, Berber B M Postmus, Remco M van den Berg, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 10, 2002
Methods to monitor response to chemotherapy in non-small cell lung cancer with 18F-FDG PETCorneline J Hoekstra, Otto S Hoekstra, Sigrid G Stroobants, et al.
Pageof 70